Colgate-Palmolive’s second-quarter revenue rose 4.9% to $5,361M, but $129M of restructuring charges helped push reported operating profit down 5.9% to $1,016M. Excluding specified costs in both periods, adjusted operating profit increased. Its everyday household and pet-care businesses remained profitable, but higher sales did not translate into more reported earnings. The distinction matters because restructuring also requires cash payments. Dollar amounts marked “M” are in millions. 2026 10-Q, income statement, Note 5 and operating profit reconciliation
1. Lower Reported Short-Term Debt Does Not Eliminate Refinancing Exposure
Colgate reduced total debt only modestly, despite a large decline in the amount classified as due within a year.
1-1. Receivables and Inventory Absorb More Resources
Read the receivables and inventory rows alongside cash: more resources were tied up in money customers owed and products awaiting sale.
| Item ($M) | Dec. 31, 2025 | June 30, 2026 | Change |
|---|---|---|---|
| Cash and equivalents | 1,288 | 1,370 | 6.4% |
| Receivables, net | 1,675 | 1,962 | 17.1% |
| Current inventory | 2,032 | 2,181 | 7.3% |
| Property, plant and equipment, net | 4,660 | 4,639 | -0.5% |
| Other intangible assets, net | 1,536 | 1,495 | -2.7% |
| Total assets | 16,330 | 16,790 | 2.8% |
| Total liabilities | 15,965 | 16,224 | 1.6% |
| Total equity, including noncontrolling interests | 365 | 566 | 55.1% |
Equity is the accounting value left after subtracting liabilities from assets; noncontrolling interests represent outside investors’ ownership in subsidiaries.
Across inventory classified as both current and noncurrent, finished goods increased from $1,479M to $1,609M, while raw materials and supplies declined from $632M to $604M. That composition warrants watching how quickly products sell, but does not establish excess inventory. The filing does not isolate every cause of the receivables increase or the modest declines in fixed and intangible assets. 2026 10-Q, balance sheet, p. 4; Note 6
1-2. Commercial Paper Replaces Maturing Bonds
Debt totaled $7,857M, versus $7,988M at year-end: $34M was classified as current and $7,823M as long-term. Commercial paper—short-term borrowing from investors—increased from $147M to $1,149M as the company refinanced maturing bonds. Colgate classifies qualifying borrowings as long-term when it intends and can refinance them, including through credit lines. The classification therefore does not eliminate the need to replace or repay those borrowings. 2026 10-Q, liquidity discussion, p. 52
Accounts payable and other accruals together rose from $5,353M to $5,704M; these operating obligations are distinct from debt. The 10-Q does not provide a complete updated percentage of debt maturing over the next three years, a weighted average interest coupon, or separate lease asset and liability balances. 2026 10-Q, balance sheet and liquidity discussion
1-3. Buybacks Keep Book Equity Small
Retained earnings rose from $26,595M to $27,085M: $1,339M of profit attributable to Colgate shareholders less $849M of declared dividends. Common stock and additional paid-in capital combined increased from $5,788M to $5,898M, while accumulated losses recorded outside net income narrowed by $63M. Treasury stock, the cost of shares held after repurchase, grew from $28,450M to $28,931M. These accumulated repurchases explain much of the small accounting equity balance; retained earnings are accumulated accounting profits, not cash available for spending. 2026 10-Q, equity statement, p. 6
2. Reported Operating Profit Falls Despite Adjusted Growth
The reported profit decline is substantially explained by restructuring, but spending on advertising also absorbed some of the benefits of higher sales.
2-1. First-Half Sales Recover While Margins Fall
The three comparable first-half periods show revenue above its earlier level, with less reported profit retained from each dollar of sales. “H1” means the six months ended June 30.
| Item ($M unless stated) | H1 2024 | H1 2025 | H1 2026 | Annualized change, 2024–26 |
|---|---|---|---|---|
| Revenue | 10,124 | 10,021 | 10,686 | 2.7% |
| Operating profit | 2,139 | 2,156 | 1,980 | -3.8% |
| Operating margin | 21.1% | 21.5% | 18.5% | — |
| Net income attributable to Colgate | 1,414 | 1,433 | 1,339 | -2.7% |
| Attributable net income / revenue | 14.0% | 14.3% | 12.5% | — |
Annualized changes express the compound yearly rate over two elapsed years. Margins divide the corresponding profit by revenue. 2025 10-Q, p. 2; 2026 10-Q, p. 2
These reported margins include different special charges. H1 2026 operating profit included $300M of restructuring charges, while H1 2025 included $15M related to pension litigation and $9M of acquisition costs. Adding back those operating charges gives $2,280M for H1 2026 versus $2,180M for H1 2025, an increase of approximately 4.6%. The reported decline therefore does not mean operating profit also fell after these exclusions. 2026 10-Q, Note 11
For Q2 alone, operating margin fell from 21.1% to 19.0%: approximately $19 of operating profit per $100 of sales. Colgate’s adjusted operating profit rose from $1,089M to $1,145M. This non-GAAP measure, which excludes specified expenses from profit reported under U.S. accounting rules, adds back $9M of acquisition costs to prior-year profit of $1,080M and $129M of restructuring to current profit of $1,016M. Those exclusions turn a reported decline into adjusted growth; they do not make the costs disappear. 2026 10-Q, operating profit reconciliation, p. 33
Reported operating leverage—the percentage profit change divided by the percentage sales change—was -1.2, using -5.9% and +4.9%. The negative result means profit fell while sales rose; restructuring makes it an unreliable guide to how future sales changes might affect profit. Diluted earnings per share, which allow for potential shares from stock awards and options, fell from $0.91 to $0.86 as attributable profit declined from $743M to $693M. The diluted share count fell from 813.3M to 801.8M, cushioning the decline by roughly $0.01 per share compared with using the prior-year share count. 2026 10-Q, Note 7
2-2. Higher Advertising Spending Offsets Part of the Gross-Margin Gain
Gross margin, the share of sales left after product costs, improved from 60.1% to 61.5%. Management attributes the improvement to cost savings, pricing and product mix—the combination of products sold—partly offset by material costs. Advertising rose from $678M to $777M, helping lift selling and administrative expenses from $1,963M to $2,130M. The filing does not quantify a complete split between costs that stay relatively stable and costs that vary with sales, so these expense categories should not be treated as purely fixed costs. 2026 10-Q, pp. 31–32
3. First-Half Free Cash Flow Matches Dividends and Buybacks on Rounded Figures
Cash generation improved, but shareholder distributions matched all cash remaining after capital spending, based on the disclosed rounded amounts.
Compare operating cash with capital expenditure—spending on assets such as facilities and equipment—before assessing how much cash could fund distributions.
| Item ($M) | H1 2025 | H1 2026 | Change ($M) |
|---|---|---|---|
| Operating cash flow | 1,484 | 1,742 | 258 |
| Investing cash flow | -560 | -244 | 316 |
| Financing cash flow | -867 | -1,414 | -547 |
| Capital expenditure | 232 | 266 | 34 |
| Free cash flow: operating cash less capital expenditure | 1,252 | 1,476 | 224 |
| Dividends paid plus treasury-share purchases | 1,396 | 1,476 | 80 |
| Period-end cash | 1,215 | 1,370 | 155 |
Free cash flow and combined distributions above are calculated from the filing’s cash-flow statement. 2026 10-Q, p. 5
Operating cash divided by consolidated net income was 1.12 in H1 2024 ($1,671M/$1,495M), 0.99 in H1 2025 ($1,484M/$1,499M), and 1.24 in H1 2026 ($1,742M/$1,401M). In the latest period, that means operations generated about $1.24 in cash for every dollar of consolidated net income, including profit belonging to outside owners of subsidiaries. These ratios measure cash conversion, not earnings reliability. 2025 10-Q, p. 5; 2026 10-Q, p. 5
The cash-flow adjustment for restructuring and termination benefits, net of cash paid, increased from negative $13M to positive $232M. This adds back expenses already deducted from profit, after allowing for related cash payments; it is not cash received from restructuring. Accounts payable and other working-capital movements added $124M, versus absorbing $248M; working capital concerns money tied up in everyday operations. Receivables and inventory together absorbed $384M, versus $149M. These differences between when expenses are recorded and when cash moves help explain why operating cash flow rose while profit fell. 2026 10-Q, cash-flow statement
Capital spending was 2.5% of sales ($266M/$10,686M); no maintenance-versus-expansion split is disclosed. Investing outflows also fell because the prior period included $293M for an acquisition. Dividends of $879M and buybacks of $597M matched $1,476M of free cash flow on the rounded figures. Debt repayments of $1,086M were largely offset by $1,053M of net short-term borrowing, so gross repayments overstate debt reduction. 2026 10-Q, p. 5 and p. 52
4. Pricing Supports Growth, but Pet-Food Volume and Legal Claims Need Watching
Underlying sales growth was more modest than the reported revenue increase.
Q2 volume grew 0.9%, pricing added 1.6%, and currency added 2.4%. Organic sales growth was 2.4%; this non-GAAP measure removes currency movements, acquisitions and divestitures to show growth in the comparable business. The acquisition contribution accounted for 0.1 percentage point of reported volume growth, leaving organic volume growth of 0.8%; adding pricing of 1.6% explains the 2.4% organic sales increase. Colgate reported a 41.3% year-to-date global toothpaste share, up 0.2 percentage points, suggesting its core franchise remained competitive. 2026 10-Q, sales discussion, p. 30
That market share measures sales value in the markets covered by the company’s data, rather than the share of toothpaste units sold worldwide. The data omit certain retail channels and typically lag by one or two months. Q2 2026 earnings release, Market Share Information
Hill’s pet-food sales rose 3.4%, but pricing increased 3.9% while volume fell 1.2%, even including an acquisition contribution. Higher revenue therefore does not demonstrate stronger unit demand. However, lower private-label pet-food sales—products sold under retailers’ brands—reduced Hill’s organic sales growth by 2 percentage points. The earnings release also identifies the company’s exit from that business, so the segment’s volume decline should not be read solely as weaker demand for Hill’s branded products. More broadly, management expected softness across the company’s categories to persist through the second half. 2026 10-Q, pp. 28–30; Q2 2026 earnings release, Full Year 2026 Guidance
Pending talc cases increased from 453 at year-end to 525. For disclosed legal and other contingencies whose possible losses could be estimated, Colgate disclosed a range from $0 to approximately $225M beyond amounts already accrued—losses already recognized in its accounts. That range is neither a forecast nor a ceiling on all legal exposure. 2026 10-Q, Note 10
5. Savings Must Arrive as Restructuring Turns Into Cash Payments
The key test is whether cost savings and demand can support earnings as restructuring payments continue. Management projects annual pretax savings of $200M–$300M once all projects are approved and implemented, against total program charges of $350M–$550M. It expects approximately 80%–90% of charges to require cash payments. 2026 10-Q, Note 5 and restructuring discussion
Sales growth and improved gross margin provide support. Pet-food volumes, partly affected by the private-label exit, warrant monitoring alongside refinancing needs and legal exposure. With first-half distributions matching free cash flow on rounded figures, sustaining buybacks alongside investment and restructuring will depend on future cash generation or other funding.
This analysis is based on filings submitted to the U.S. Securities and Exchange Commission and is provided for informational purposes only. It is not investment advice. Source: SEC Form 10-Q, filed July 31, 2026, accession 0000021665-26-000042; historical comparisons use the Form 10-Q filed August 1, 2025. Additional context comes from the company’s July 31, 2026 earnings release furnished with Form 8-K. Figures are consolidated and unaudited; dollar amounts are in millions unless stated otherwise. Calculations use disclosed rounded amounts.